Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Colorcon
Boehringer Ingelheim
Harvard Business School

Last Updated: January 28, 2023

Investigational Drug Information for Oteracil


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Oteracil?

Oteracil is an investigational drug.

There have been 83 clinical trials for Oteracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Ono Pharmaceutical Co. Ltd.

There are four hundred and thirty-four US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Oteracil
TitleSponsorPhase
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric CancerTianjin Medical University Cancer Institute and HospitalPhase 2
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung CancerAnhui Chest HospitalPhase 2
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With Previously Untreated HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) CanceSecond Hospital of Lanzhou UniversityPhase 2

See all Oteracil clinical trials

Clinical Trial Summary for Oteracil

Top disease conditions for Oteracil
Top clinical trial sponsors for Oteracil

See all Oteracil clinical trials

US Patents for Oteracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Oteracil See Plans and Pricing Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) See Plans and Pricing
Oteracil See Plans and Pricing Aryl-cyanoguanidine compounds Bayer Pharma Aktiengesellschaft (Berlin, DE) See Plans and Pricing
Oteracil See Plans and Pricing Metal-salen complex compound, local anesthetic and antineoplastic drug IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP) See Plans and Pricing
Oteracil See Plans and Pricing Multimodal silica-based nanoparticles See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Oteracil

Drugname Country Document Number Estimated Expiration Related US Patent
Oteracil Argentina AR098961 2033-12-23 See Plans and Pricing
Oteracil Australia AU2014372833 2033-12-23 See Plans and Pricing
Oteracil Brazil BR112016014830 2033-12-23 See Plans and Pricing
Oteracil Canada CA2934617 2033-12-23 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Colorcon
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.